Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

Mansi Shah, MD
Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

June 11th 2025

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

June 7th 2025

IVBM Phoenix logo | Image: AJMC
Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

May 19th 2025

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

May 17th 2025

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

April 25th 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Continuing Medical Education
View All
June 14th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
June 14th 2025

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
June 14th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
June 14th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

More News

cells
May 8th 2022

Energy Metabolism in Clonal Plasma Cells May Drive Survival Outcomes in Newly Diagnosed MM

Jaime Rosenberg
The findings, say the researchers, provide a basis for future exploration of the activity of energy metabolism pathways in clonal plasma cells of patients newly diagnosed with the disease.
health graphic
May 4th 2022

Levels of Certain Thyroid Hormone May Help With Risk Stratification in MM

Jaime Rosenberg
With survival of multiple myeloma ranging from less than 1 month to over 10 years, the researchers highlighted the importance of risk stratification to quickly identify patients who are high risk with poor prognosis and could benefit from different treatment strategies and close surveillance.
diversity graphic
May 3rd 2022

Researchers Show How RWD on Racial Outcomes in MM Can Complement Clinical Trial Data

Jaime Rosenberg
Of the 5800 patients included in study, 20% were Black, which the researchers say adequately represents disease incidence among the population.
Incorporating RWE Into Future Decision-Making
April 26th 2022

Incorporating RWE Into Future Decision-Making

Our panel concludes with their plans to incorporate RWE into MM management in the future.
MM Unmet Needs
April 26th 2022

MM Unmet Needs

Dr Baljević discusses unmet needs that are typically seen in the management of MM.
doctor with patient in hospital bed
April 26th 2022

Predicting Early Severe Infection in Patients With Newly Diagnosed MM

Laura Joszt, MA
A simple score can identify the patients at risk of severe infection within 4 months of initiating treatment, highlighting candidates to be treated with prophylactic antibiotics.
Kidneys
April 23rd 2022

Study Finds Autologous Stem Cell Transplantation Safe, Effective in Patients With Multiple Myeloma, Chronic Kidney Disease

Rose McNulty
Chronic kidney disease is a common complication in multiple myeloma, and a recent study found it is safe to treat this patient population with autologous stem cell transplantation.
Image of words multiple myeloma
April 22nd 2022

Mesenchymal Stem Cells Induce Cell Proliferation, Inhibit Dexamethasone Effectiveness in MM

Rose McNulty
Mesenchymal stem cells are known to promote tumor growth and metastasis in multiple myeloma (MM), but a recent study found they may also inhibit the effects of the corticosteroid dexamethasone, a common medication for the hematologic malignancy.
Educating on RWE
April 20th 2022

Educating on RWE

Dr Richter delves into how we can better educate patients and physicians on RWE to improve decision-making.
MM and Non-Comparative RWE
April 20th 2022

MM and Non-Comparative RWE

The panel moves the discussion to non-comparative RWE and how that can play a part in their decision-making for MM therapy.
heart image
April 14th 2022

Higher Risk of CV Mortality Seen in Patients With MM Compared With General Population

Rose McNulty
While studies have explored risks among patients with multiple myeloma, recent research is the first to compare cardiovascular mortality risk in multiple myeloma to that of the general population.
RWE Decision-Making Barriers
April 12th 2022

RWE Decision-Making Barriers

Dr Beveridge explains potential barriers a physician can encounter when implementing RWE into MM therapy.
Incorporating RWE in MM Decision-Making
April 12th 2022

Incorporating RWE in MM Decision-Making

The panel elaborate on how they’ve incorporated RWE into their decision-making processes for their patients with MM.
a magnifying glass over a report with a 3D graph on it
April 11th 2022

New Minimal Residual Disease Assessment Could Detect Disease Progression Earlier in MM

Skylar Jeremias
Flow–minimal residual disease (MRD) assessment in patients with multiple myeloma (MM) was found to be a good tool for early detection of MRD and could aid providers in treatment decision-making.
Image of health care costs
April 9th 2022

Study Finds Potential Association Between Allostatic Load, Worse Overall Survival in MM

Rose McNulty
A recent study aimed to identify associations between socioeconomic status, allostatic load, and clinical trial end points in patients with multiple myeloma (MM).
The Value of RWE in MM
April 5th 2022

The Value of RWE in MM

Jay Weaver, PharmD, MPH, and Muhamed Baljević, MD, FACP, discuss how RWE can affect the management of MM.
MM and Real-World Evidence
April 5th 2022

MM and Real-World Evidence

Dr Richter relays some of the differences between real-world evidence (RWE) and RCT data, as well as how they can work together when determining therapy.
Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says
April 2nd 2022

Early Treatment Matters More Than Ever in Multiple Myeloma, Kumar Says

Mary Caffrey
Whether a patient is refractory to initial treatment dictates the future course of care.
Image of scientific research
March 30th 2022

Review Examines Growing Treatment Options for Heavily Refractory MM

Jared Kaltwasser
Relapse remains a daunting reality in multiple myeloma, but clinicians have more tools to work with to fight the disease.
MM and the Limitations of RCT Data
March 29th 2022

MM and the Limitations of RCT Data

Dr Baljević explain some of the limitations physicians can come across with applying randomized clinical trial (RCT) data to MM treatment.
Decision Support Tools for MM
March 29th 2022

Decision Support Tools for MM

A panel of experts elaborate on the decision support tools that are utilized by physicians to give patients high-value regimens.
Scale to measure weight
March 25th 2022

Obesity Increases Risk of MM Precursor, While Weight Loss Indicates Risk of Cancer Diagnosis

Laura Joszt, MA
Weight and changes in it can indicate implications for cancer risk and cancer diagnosis, according to 2 abstracts being presented at the American Association for Cancer Research Annual Meeting.
MM Healthcare Resource Utilization
March 22nd 2022

MM Healthcare Resource Utilization

The panel discusses the data used to evaluate healthcare resources for MM therapy, as well as economic burden.
MM From the Payers’ Perspective
March 22nd 2022

MM From the Payers’ Perspective

Dr Beveridge provides a payer’s perspective on the available regimens for MM treatment.
man holding a tablet that is projecting different graphs
March 22nd 2022

New Risk Prediction Model for MM Outcomes Found Easy to Use, Implement in Clinical Practice

Skylar Jeremias
A new frailty-based outcome prediction model for multiple myeloma (MM) was found to be an easy-to-use tool in clinical practice and produced valid results based on a large real world cohort of patients with a new MM diagnosis, according to a recent study.
dna surrounded by data
March 18th 2022

Multi-Tiered Risk Stratification Model for MM May Perform Better Than Standard Systems

Skylar Jeremias
Risk stratification is a difficult process for multiple myeloma (MM), and authors concluded that their multi-tiered model may provide a greater risk assessment benefit than standard stratification systems.
MM and Regimens for First- and Second-Line Treatment
March 15th 2022

MM and Regimens for First- and Second-Line Treatment

Joshua Richter, MD, and Roy Beveridge, MD, explain the role triplet regimens play in MM treatment and how physician decision-making has been impacted since the NCCN guidelines have expanded the list of acceptable first- and second-line treatment options.
A Multiple Myeloma Overview
March 15th 2022

A Multiple Myeloma Overview

Muhamed Baljević, MD, FACP, provides a background of multiple myeloma (MM) within the past five years and the main treatment options.
a bottle of pils with a clipart image of an orangle slice and the words "vitamin D and multiple myeloma" written
March 11th 2022

Addressing Low Vitamin D Levels May Reduce Risk of Peripheral Neuropathy in MM

Skylar Jeremias
Researchers found that low levels of vitamin D and the prevalence of peripheral neuropathy were common in patients with multiple myeloma, suggesting that addressing the former could help prevent the latter.
doctor comforting patient in a hospital bed
March 8th 2022

Study Finds Decorin May Have Protective Effect in Multiple Myeloma

Skylar Jeremias
Decorin, a highly conserved, class 1 small leucine-rich repeat proteoglycan expressed in the extracellular matrix, may have a protective effect in a subset of patients with multiple myeloma, investigators concluded.
<1
...
567891011>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo